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Abstract
Background: Antimuscarinic agents are the most popular treatment for overactive bladder and
their efficacy in man is well documented, producing decreased urinary frequency and an increase
in bladder capacity. During cystometry in rats, however, the main effect reported after acute
treatment with antimuscarinics is a decrease in peak micturition pressure together with little or no
effect on bladder capacity. In the present experiments we studied the effects, in rats, of the two
most widely used antimuscarinic drugs, namely oxybutynin and tolterodine, utilising several
different cystometrographic conditions. The aim was to determine the experimental conditions
required to reproduce the clinical pharmacological effects of antimuscarinic agents, as seen in
humans, in particular their ability to increase bladder capacity.
Results: Intravenous or oral administration of tolterodine or oxybutynin in conscious rats utilized
1 day after catheter implantation and with saline infusion at constant rate of 0.1 ml/min, gave a dose-
dependent decrease of micturition pressure (MP) with no significant change in bladder volume
capacity (BVC). When the saline infusion rate into the bladder was decreased to 0.025 ml/min, the
effect of oral oxybutynin was similar to that obtained with the higher infusion rate. Also,
experiments were performed in rats in which bladders were infused with suramin (3 and 10 µM)
in order to block the non-adrenergic, non-cholinergic component of bladder contraction. Under
these conditions, oral administration of oxybutynin significantly reduced MP (as observed
previously), but again BVC was not significantly changed.
In conscious rats with bladders infused with diluted acetic acid, both tolterodine and oxybutynin
administered at the same doses as in animals infused with saline, reduced MP, although the
reduction appeared less marked, with no effect on BVC.
In conscious rats utilized 5 days after catheter implantation, a situation where inflammation due to
surgery is reduced, the effect of tolterodine (i.v.) and oxybutynin (p.o.) on MP was smaller and
similar, respectively, to that observed in rats utilized 1 day after catheter implantation, but the
increase of BVC was not statistically significant.
In anesthetized rats, i.v. administration of oxybutynin again induced a significant decrease in MP,
although it was of questionable relevance. Both BVC and threshold pressure were not significantly
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reduced. The number and amplitude of high frequency oscillations in MP were unmodified by
treatment.
Finally, in conscious obstructed rats, intravenous oxybutynin did not modify frequency and
amplitude of non-voiding contractions or bladder capacity and micturition volume.
Conclusion:  Despite the different experimental conditions used, the only effect on
cystometrographic parameters of oxybutynin and tolterodine in anesthetized and conscious rats
was a decrease in MP, whereas BVC was hardly and non-significantly affected. Therefore, it is
difficult to reproduce in rats the cystometrographic increase in BVC as observed in humans after
chronic administration of antimuscarinic agents, whereas the acute effects seem more similar.
Background
Overactive bladder is a chronic clinical syndrome charac-
terized by urgency and frequency with or without urinary
incontinence affecting millions of people worldwide
[1,2]. Overactive bladder arises from uncontrolled con-
traction of the detrusor muscle during bladder filling [3].
Although what element(s) trigger(s) unstable contraction
is not resolved; myogenic [4] or neural [5] theories have
been suggested in the attempt to clarify the etiology of this
bladder dysfunction.
Nevertheless, since contraction of the detrusor muscle and
bladder emptying are primarily mediated by stimulation
of muscarinic receptors by acetylcholine, anticholinergic
agents are currently recommended as a first-line therapy
for overactive bladder. Of the available antimuscarinic
agents, oxybutynin and tolterodine are the most widely
used to treat this condition [6,7].
As demonstrated by several investigations in patients, oxy-
butynin decreases urinary frequency, urgency and epi-
sodes of urge incontinence, in addition to increasing
bladder volume at first desire to void, enhancing maxi-
mum bladder capacity and reducing maximum detrusor
pressure during filling [6,8]. Similar results have been
reported after administration of tolterodine in patients
affected by overactive bladder [[6], and references
therein].
Despite the favourable results observed in the clinical
studies reported above with regard to the cystometro-
graphic modifications induced by treatment with oxybu-
tynin and tolterodine, the only effect generally observed
in rats is a decrease in the maximum detrusor pressure at
micturition [9-18].
Although purinergic mechanisms appear not to be
involved to any extent in the normal function of human
bladder [19], they are involved in human pathological
conditions [19], and they are well documented for con-
traction of rat urinary bladder [20].
The aim of the present experiments was, therefore, to
study the effect of oxybutynin and tolterodine in rats,
using different cystometrographic conditions, attempting
to find suitable experimental conditions able to reproduce
the effects observed in humans, in particular the increase
of bladder capacity.
A preliminary account of this work was presented in an
abstract [21].
Results
Tolterodine and oxybutynin were evaluated as the most
widely utilized antimuscarinics.
In general, 2–3 scaled doses of each compound were
administered. In some pilot experiments each dose of
compound was tested with a matched control group
treated with vehicle. In other experiments, control rats
and animals treated with different doses of test com-
pound were evaluated simultaneously.
Effect of intravenous and oral administration in conscious 
rats utilized 1 day after catheter implantation
When i.v. injected in conscious rats, oxybutynin (0.3 mg/
kg) induced a prompt and marked reduction of MP show-
ing a peak 15 min after injection. BVC, in contrast, was
not modified in comparison with the values observed in
control animals. Similar results were obtained after
administration of the same dose of tolterodine (Fig. 1).
After different doses of both antimuscarinics administra-
tion, a dose-dependent reduction of MP was observed,
with no significant changes of BVC, tolterodine being sub-
stantially more potent than oxybutynin (Fig. 2). After oral
administration of oxybutynin (3 mg/kg) and tolterodine
(10 mg/kg), the time-course of BVC and MP values in con-
trol and treated animals was similar to that observed after
i.v. administration (Fig. 3). The compounds induced a
marked and statistically significant fall of MP reaching a
peak 1 hr after administration with no significant effects
on BVC. Dose-response curves obtained after administra-
tion of the antimuscarinics are shown in Fig. 4. Oxybu-
tynin and tolterodine dose-dependently decreased MP.BMC Pharmacology 2005, 5:14 http://www.biomedcentral.com/1471-2210/5/14
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Time-course of the effect of i.v. administration of oxybutynin and tolterodine on BVC and MP in conscious rats Figure 1
Time-course of the effect of i.v. administration of oxybutynin and tolterodine on BVC and MP in conscious 
rats. Data represent the mean (± S.E.) of BVC (ml) and MP (mmHg) values recorded before treatment (0 min) and at different 
times after administration of: upper panel – vehicle (0.1 ml/kg; circles; n = 6) or oxybutynin (0.3 mg/kg; squares; n = 8); lower 
panel – vehicle (0.1 ml/kg; circles; n = 7) or tolterodine (0.3 mg/kg; squares n = 8). Rats were utilized 1 day after catheter 
implantation. Statistical analysis indicates significativity vs vehicle-treated group at considered times.
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The effects of oral administration of oxybutynin (3 mg/
kg) were also evaluated in freely-moving rats using dis-
continuous cystometry, increasing observation period up
to 10 hr after treatment. Discontinuous cystometry allows
parameters to be recorded for extended periods of time,
avoiding the detrimental effects on the levels of basal
physiological urodynamic parameters seen in restrained
rats following continuous bladder infusion for a long time
(for example decrease in peak micturition pressure). Oxy-
butynin induced a decrease of MP similar to that observed
previously during the first 2–4 hr after treatment (see Fig.
5 and the corresponding Fig. 3). The difference between
treated and control group resulted statistically significant
in spite of the figure course because it should be consid-
ered that it was evaluated on ∆ values, as reported in the
Method section. BVC values resulted significantly (p <
0.05) different in comparison with vehicle treated ani-
mals at 4 hr after administration. This result, in contrast to
that previously obtained during classical cystometry, how-
ever, can be related to the behaviour of the control group,
whose BVC values were extremely constant during the
period.
To further study the effect of oxybutynin on BVC, the less
inhibitory dose of oxybutynin on MP (oral dose of 1 mg/
kg) was chosen and the saline infusion rate into the blad-
der was decreased from 0.1 ml/min to 0.05 and 0.025 ml/
min. However, the effect of oxybutynin on BVC and MP
was found to be similar to that obtained with the higher
flow rate (Fig 6).
In order to block the non-adrenergic, non-cholinergic
component of the contraction, experiments were per-
formed in rats with bladders infused with suramin (3 and
10 µM). Suramin (10 µM) in vehicle-treated rats induced
a significant increase (in comparison with basal values) in
BVC (p < 0.01). Under these conditions, oral administra-
tion of 3 mg/kg of oxybutynin reduced significantly MP
(as previously observed), but BVC was again not signifi-
cantly increased (Fig 7). In normal unanesthetized rats,
Igawa et al. [20] found that co-administration of atropine
in rats with purinergic receptors desensitised by adminis-
tration of α,β-methylene ATP induced urinary retention.
In our experimental conditions, we did not observed over-
flow incontinence in rats with bladder infused with
suramin and treated with oxybutynin, probably owing to
the fact that suramin is not a specific antagonist [19] and,
therefore, not all the P2X receptors were inhibited.
Effect of intravenous and oral administration in conscious 
rats treated 5 days after catheter implantation
Catheterization of the bladder induces inflammation that
reaches a peak between 1–3 days after surgery. At 5 days
post catheterization, inflammation is considerably lower
than at 1 day after catheter implantation, as confirmed by
Effect of i.v. administration of tolterodine and oxybutynin on  BVC and MP in conscious rats Figure 2
Effect of i.v. administration of tolterodine and oxybu-
tynin on BVC and MP in conscious rats. Data represent 
the mean (± S.E.) AUC change of BVC and MP calculated as 
reported in the Method Section. Tolterodine was adminis-
tered at 0.03 (n = 8), 0.1 (n = 9) and 0.3 (n = 8) mg/kg; oxy-
butynin at 0.1 (n = 5) and 0.3 (n = 8) mg/kg. Corresponding 
open bars represent changes recorded in the vehicle groups 
(n = 7). Rats were utilized 1 day after catheter implantation. 
Statistical significance was evaluated by ANOVA (and Dun-
nett's test).
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Time-course of the effect of oral administration of oxybutynin and tolterodine on BVC and MP in conscious rats Figure 3
Time-course of the effect of oral administration of oxybutynin and tolterodine on BVC and MP in conscious 
rats. Data represent the mean (± S.E.) of BVC (ml) and MP (mmHg) values recorded before treatment (0 min) and at different 
times after administration of: upper panel – vehicle (2 ml/kg; circles; n = 7) or oxybutynin (3 mg/kg; squares; n = 7); lower panel 
– vehicle (2 ml/kg; circles; n = 7) or tolterodine (10 mg/kg; squares n = 8). Rats were utilized 1 day after catheter implantation. 
Statistical analysis indicates significativity vs vehicle-treated group at considered times.
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the higher values of BVC recorded (about 1.3 – 1.7 ml,
data not shown) than those at 1 day after surgery (see
basal values in Fig 1 and 3). Under these conditions, i.v.
administration of tolterodine dose-dependently
decreased MP without affecting BVC (Fig. 8). The effect of
tolterodine on MP was less than that observed in rats 1
day after surgery. The effect of oral administration of
oxybutynin (1 mg/kg) on BVC and MP was not substan-
tially different from that observed in rats utilized 1 day
after catheter implantation.
Effect of intravenous administration in anesthetized rats
Cystometrographic and electromyographic recordings
performed during micturition in rats under anesthesia
show that the striated muscle of external urethral sphinc-
ter (EUS) exhibits high-frequency bursting that induces
corresponding high-frequency oscillations (HFO) in the
pressure recorded intravescically. HFO are correlated with
the bursting pattern in the EUS, and represent alternate
contractions and relaxations of the urethral outlet, func-
tioning like a pump to enhance urine flow. Consequently,
pharmacological manipulations that may result in
impaired EUS function might result in micturition distur-
bances, e.g. bladder-urethra dyssynergia.
In anesthetized rats, the i.v. administration of 0.3 mg/kg
of oxybutynin (a dose inducing in conscious rats a signif-
icant decrease of MP) induced again a significant,
although not so relevant decrease of MP, probably owing
to the lower basal value of this parameter due to the
anesthesia. Neither BVC nor threshold pressure showed a
significant reduction. The number and amplitude of HFO
were not modified by oxybutynin.
Effect of intravenous administration in conscious rats with 
bladder infused with diluted acetic acid
Bladders of conscious rats catheterized from 1 day were
infused for a control period of 60 min with saline. Then
the infusion was switched to 0.2% acetic acid. At the end
of the first hour of bladder infusion with the irritant, BVC
was markedly and significantly reduced (about 40 – 60%;
p < 0.01) in all groups of animals, indicating bladder
hyperactivity due to pain and an increase in afferent nerve
firing. Micturition pressure was less affected and generally
increased (Fig. 9).
In the groups of animals treated with vehicle, the contin-
uous infusion of the bladder with acetic acid during the
second hour of experiment induced a further decrease of
bladder capacity (generally 10–30%), although this fur-
ther reduction was not statistically significant. MP did not
change during the period. Oxybutynin (1 mg/kg i.v.) and
tolterodine (0.3 mg/kg i.v.) had no effect on BVC, but
caused a rapid and marked decrease of MP similar to that
Effect of oral administration of tolterodine and oxybutynin  on BVC and MP in conscious rats Figure 4
Effect of oral administration of tolterodine and oxy-
butynin on BVC and MP in conscious rats. Data repre-
sent the mean (± S.E.) AUC change of BVC and MP 
calculated as reported in the Method Section. Tolterodine 
was administered at 1 (n = 6), 3 (n = 7) and 10 (n = 8) mg/kg; 
oxybutynin at 1 (n = 7) and 3 (n = 7) mg/kg. Corresponding 
open bars represent changes recorded in the vehicle groups 
(n = 7). Rats were utilized 1 day after catheter implantation. 
Statistical significance was evaluated by ANOVA (and Dun-
nett's test).
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observed in rats during saline infusion of the bladder (Fig.
9).
After the administration of the same i.v. doses as utilized
in normal, saline-infused rats, both tolterodine and oxy-
butynin reduced MP, although the reduction appeared
less marked (Fig. 10). The antimuscarinics generally
showed only a trend to reverse the decrease in BVC
observed during the second hr of acid infusion. However,
the intermediate dose of tolterodine produced a
significant difference (p < 0.05) between control and
treated rats with regard to BVC.
Effect of intravenous administration in conscious 
obstructed rats
In rats, bladder hypertrophy secondary to bladder outlet
obstruction induces bladder instability characterized by
the presence of non-voiding contractions (NVC) during
filling. Repeated cystometry in control obstructed rats
injected with saline gave reproducible results in terms of
frequency and amplitude of spontaneous contractile
activity (NVC). BVC and MV in these animals were also
not significantly changed. Oxybutynin (0.3 mg/kg i.v.)
gave results similar to control animals (Table 2).
Time-course of the effect of oral administration of oxybutynin on BVC and MP in conscious freely-moving rats under discontin- uous cystometry Figure 5
Time-course of the effect of oral administration of oxybutynin on BVC and MP in conscious freely-moving rats 
under discontinuous cystometry. Data represent the mean (± S.E.) of BVC (ml) and MP (mmHg) values recorded before 
treatment (0 min) and at different times after administration of vehicle (2 ml/kg; circles; n = 11) or oxybutynin (3 mg/kg; 
squares; n = 11).
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Discussion
A summary of the different models and conditions uti-
lized to evaluate the effects of tolterodine and/or oxybu-
tynin is shown in Table 3.
Cystometrographic evaluation performed in conscious
normal rats utilized one day after catheter implantation
showed that neither oxybutynin nor tolterodine increased
BVC after oral or i.v. administration. In agreement with
previously reported data [9,13,15,16], however, both
drugs induced a strong dose-dependent decrease of MP.
Furthermore, this behaviour was maintained when a
discontinuous cystometry was performed or when differ-
ent filling rates were utilized.
Available evidence indicates that arachidonic acid metab-
olites produced along the cyclooxygenase pathway are
involved in the physiological regulation of micturition
during reflex activation of the urinary bladder. Further-
more, endogenous prostaglandins are produced locally
following distension of the bladder wall and modulate
the afferent branch of reflex micturition by lowering the
threshold for eliciting voiding contractions, serving as a
link between detrusor muscle stretch produced by bladder
filling and activation of capsaicin-sensitive afferents [22-
25]. Different authors [26,27] have shown that
cystometrograms in conscious rats with bladders infused
with saline and recorded during the first 1–3 days after
catheter implantation showed bladder overactivity with
relatively low urine volume and a high frequency of
Effect of oral administration of oxybutynin on BVC and MP in conscious rats under cystometry at different infusion rates Figure 6
Effect of oral administration of oxybutynin on BVC and MP in conscious rats under cystometry at different 
infusion rates. Data represent the mean (± S.E.) AUC change of BVC and MP calculated as reported in the Method Section. 
Oxybutynin was administered at 1 mg/kg (n = 9). Corresponding open bars represent changes recorded in the vehicle groups 
(n = 8). Infusion rates utilized were 0.025 and 0.05 ml/min. Rats were utilized 1 day after catheter implantation. Statistical signif-
icance was evaluated by Student's t test.
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micturition. Cystitis is also present at this time and is char-
acterized by edema in the submucosa and an increased tis-
sue content of prostaglandins that stimulate capsaicin-
sensitive sensory fibers in the afferent branch of the mic-
turition reflex [27]. In the present study, cystometro-
graphic recordings performed in conscious rats one day
after catheter implantation and during saline infusion of
bladder, confirmed that bladder capacity is significantly
reduced in comparison with BVC values observed 5 days
after catheter implantation, as previously reported [27]. It
is therefore conceivable that in our experiments, per-
formed under conditions of bladder inflammation, that a
strong influence of prostaglandin levels on afferent firing
was present. On the other hand, when the activity of
oxybutynin or tolterodine was evaluated in rats 5 days
after catheter implantation, the same effect as seen after 1
day, still occurred; namely, a decrease in MP with no
change in BVC. These results indicate that the involve-
ment of the inflammatory mediators is not the reason for
the lack of antimuscarinic activity on BVC.
The involvement of ATP in non adrenergic, non choliner-
gic (atropine-resistant) contraction of urinary bladder is
well documented [20]. Recently, it has also been
demonstrated that ATP is released from the urothelium of
isolated urinary bladder following increased intraluminal
pressure [28]. Furthermore, it has been reported that
intravesical ATP stimulates the micturition reflex in
awake, freely moving rats [29] and that during cystometry
the number of impulses generated in the afferent neurons
was halved by treatment with suramin [19].
Consequently, suramin infusion into rat bladder has been
Effect of oral administration of oxybutynin on BVC and MP in conscious rats with bladder infused with different suramin  concentrations Figure 7
Effect of oral administration of oxybutynin on BVC and MP in conscious rats with bladder infused with differ-
ent suramin concentrations. Data represent the mean (± S.E.) AUC change of BVC and MP calculated as reported in the 
Method Section. Oxybutynin was administered at 3 mg/kg (n = 8). Corresponding open bars represent changes recorded in the 
vehicle groups (n = 8). Suramin concentrations were 3 × 10-6 and 1 × 10-5 M. Rats were utilized 1 day after catheter implanta-
tion. Statistical significance was evaluated by Student's t test.
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reported to increase BVC [30]. Outflow obstruction may
be associated with changes in the cholinergic function of
the bladder associated with an increase of atropine-resist-
ance. Again, the bladder instability seen in obstructed rats
seems to be particularly related to the atropine-resistant
contraction component, where ATP and prostaglandins
play an important role [14]. However, we found that oxy-
butynin did not increase BVC either in rats under infusion
of the bladder with suramin, or in obstructed rats. In addi-
tion, in this last experimental condition, oxybutynin did
not modify the frequency and amplitude of the non-void-
ing contractions. These findings are in agreement with the
lack of activity shown by tolterodine in the same model
[31], whereas Kwak and Lee [14] reported a significant
decrease of frequency and amplitude of the non voiding
contractions in anesthetized rats after intraarterial admin-
istration of 1 mg/kg oxybutynin.
Although the mechanism of action of antimuscarinic
agents used for the treatment of overactive bladder (such
as oxybutynin and tolterodine) is thought to be due
mainly to suppression of detrusor contraction through
blockade of M3 muscarinic receptors on detrusor smooth
muscle, an effect on central muscarinic receptors, located
in the brain cannot be ruled out as both compounds pass
into the central nervous system [32].
Effects on the lower urinary tract of drugs acting on central
nervous system muscarinic receptors have been reported
by several investigators [17,33-35] Following i.c.v. or i.t.
administration in conscious normal rats of oxotremorine
methiodide, a muscarinic agonist, a dose-dependent
increase of BVC was observed. The muscarinic antagonist
atropine did not change BVC after i.t. administration, and
increased BVC after i.c.v. administration only in very high
doses [36]. Both oxybutynin and tolterodine i.c.v. admin-
istered showed no (oxybutynin) or little (tolterodine)
augmenting effect on BVC [17]. On the other hand, sev-
eral Authors reported that oral oxybutynin administered
in conscious rats with lesions at the basal forebrain
[11,18], increases BVC. These findings seem to indicate
that the inhibitory muscarinic mechanisms that can be
activated by exogenously administered agonists seem to
be inactive under normal conditions [36], but are working
in lesioned animals. These considerations, therefore, can
explain the lack of central activity on BVC of antimus-
carinics tested in conscious normal rats.
Muscarinic receptors are also found on bladder urothelial
cells, where their density may be even higher than in
detrusor muscle. Evidence has been reported for a release
of acetylcholine from urothelium and/or nerves during
bladder filling, and acetylcholine may act directly on affer-
ent nerves to initiate the micturition reflex or to enhance
the myogenic contractile activity of the detrusor. If this is
Effect of tolterodine and oxybutynin on BVC and MP in con- scious rats utilized 5 days after catheter implantation Figure 8
Effect of tolterodine and oxybutynin on BVC and MP 
in conscious rats utilized 5 days after catheter 
implantation. Data represent the mean (± S.E.) AUC 
change of BVC and MP calculated as reported in the Method 
Section. Tolterodine was i.v. administered at 0.1 (n = 7) and 
0.3 (n = 7) mg/kg (upper panel). Oxybutynin was adminis-
tered at 1 mg/kg (n = 7; lower panel). Corresponding open 
bars represent changes recorded in the vehicle groups (n = 
7). Statistical significance was evaluated by ANOVA (and 
Dunnett's test).
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Time-course of the effect of i.v. administration of oxybutynin and tolterodine on BVC and MP in conscious rats with bladder  infused with diluted acetic acid Figure 9
Time-course of the effect of i.v. administration of oxybutynin and tolterodine on BVC and MP in conscious rats 
with bladder infused with diluted acetic acid. Data represent the mean (± S.E.) of BVC (ml) and MP (mmHg) values 
recorded before acetic acid infusion (-60 min), at the end of the first hr of acid infusion (0 min) and at different times after 
administration of: upper panel – vehicle (0.1 ml/kg; circles; n = 8) or oxybutynin (1 mg/kg; squares; n = 8); lower panel – vehicle 
(0.1 ml/kg; circles; n = 7) or tolterodine (0.3 mg/kg; squares n = 8). Rats were utilized 1 day after catheter implantation and 
during continuous infusion of acid. Statistical analysis indicates significativity vs vehicle-treated group at considered times.
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correct, blockade of muscarinic receptors should be
expected to reduce bladder tone during storage and to
increase bladder capacity. This effect is observed after
treatment with antimuscarinics in normal individuals as
well as in patients with detrusor overactivity [37]. In con-
scious rats, however, infravescical administration of
different concentrations of oxybutynin did not increased
BVC, but significantly decreased MP [12]. Furthermore,
Kim et al. [38] recently showed that bladder infusion of
different antimuscarinic agents (including oxybutynin) at
concentrations equivalent to urine concentration in
humans with oral application of these drugs, did not
modified BVC when tested in normal rats but only inhib-
ited bladder overactivity induced by intravesical instilla-
tion of carbachol.
Conclusion
Despite the different experimental conditions utilized, the
main effect of the antimuscarinics tested on cystometro-
graphic parameters in anesthetized and conscious rats is a
decrease of MP, whereas BVC is hardly and, generally,
non-significantly affected, suggesting that the block of
bladder muscarinic receptors is the only mechanism that
can be affected and evaluated after treatment with these
compounds in this animal species.
Although urodynamic assessment showed significant
comparable increases in bladder capacity following
repeated treatment with oxybutynin and tolterodine in
humans [6,7], the published papers reporting the acute
effect of these antimuscarinics in man are confusing, since
oxybutynin seems devoid of effect [39], whereas
tolterodine increased the volumes at which subjects expe-
rienced the first sensation of bladder filling and normal
desire to void [40]. It seems therefore difficult to repro-
duce in rats the cystometrographic effects observed in
humans after chronic administration of these com-
pounds. The effects observed in rats after acute adminis-
tration (although obtained at doses about 10–100-fold
higher than those used in ref. 39 and 40) seem more sim-
ilar to those recorded in patients treated with a single
dose, with the exception of the modification in symptoms
that can not be recorded in animals.
Methods
The effects of the tested compounds on rats urodynamic
parameters were evaluated by cystometrographic models
in conscious and anesthetized animals. In anesthetized or
obstructed animals (i.v. administration only) cystometry
was performed on female rats (250–350 g b.w.). Con-
scious male rats (300–400 g b.w.) were used to evaluate
the effect of tested compounds both after i.v. and oral
administration.
Effect of i.v. administration of tolterodine and oxybutynin on  BVC and MP in conscious rats with bladder infused with  diluted acetic acid Figure 10
Effect of i.v. administration of tolterodine and oxybu-
tynin on BVC and MP in conscious rats with bladder 
infused with diluted acetic acid. Data represent the 
mean (± S.E.) AUC change of BVC and MP calculated as 
reported in the Method Section (basal values were those 
recorded at the end of the first hr of acid infusion). Tolterod-
ine was administered at 0.03 (n = 7), 0.1 (n = 6) and 0.3 (n = 
8) mg/kg; oxybutynin at 0.1 (n = 8) and 0.3 (n = 8) mg/kg. 
Corresponding open bars represent changes recorded in the 
vehicle groups (n = 7). Rats were utilized 1 day after catheter 
implantation. Statistical significance was evaluated by 
ANOVA (and Dunnett's test) or Student's t test.
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Animals were housed with free access to food and water
and maintained on a forced 12 hr light-dark cycle at 20–
24°C for at least one week before the experiments were
carried out. The animals were handled according to inter-
nationally accepted principles for the care and welfare of
laboratory animals (E.E.C. Council Directive 86/609, O. J.
no L358, 18/12/86).
Surgical procedures
To obtain bladder outlet obstruction, female rats were
anesthetized with intraperitoneal administration of 3 ml/
kg of equithensin solution (pentobarbital g 1.215, chloral
hydrate g 5.312, magnesium sulphate g 2.657, ethanol ml
12.5, propylene glycol ml 49.5, distilled water to 125 ml
of final volume) and then the bladder and proximal ure-
thra were exposed via a lower abdominal midline inci-
sion. A silk ligature was placed around the urethra and
tied in the presence of an intraluminally placed indwell-
ing polyethylene cannula with an outside diameter of
1.22 mm. After removing the polyethylene cannula, the
abdominal wall was sutured and then antibiotic
medication (penicillin G 200,000 I.U./kg and streptomy-
cin 300,000 I.U./kg i.m.) was administered. Obstructed
rats were utilized for cystometry 3 weeks after urethral
ligature.
To insert the catheter into the bladder, female rats were
anesthetized with subcutaneous injection of urethane
1.25 g/kg (5 ml/kg). Animals were then placed in a supine
position and an approximately 10 mm midline incision
was made in the shaved and cleaned abdominal wall. The
urinary bladder was gently freed from adhering tissues,
emptied and then cannulated, via an incision at the dome,
with a polyethylene cannula (ID 0.58 mm, OD 0.96 mm),
which was permanently sutured with silk thread. For i.v.
injection, another polyethylene cannula with the same
characteristics and filled with heparine (40 UI/ml) in
physiological saline was inserted into the jugular vein.
Obstructed female or male rats utilized 1 or 5 days after
surgery were anesthetized with i.p. injection of
equithensin (3 ml/kg) and catheters implantation was
performed as above.
In female rats utilized upon anesthesia, the cannulae were
exteriorized through a subcutaneous tunnel in the breast-
bone area. In male and female rats awake utilized, the can-
nulae were exteriorized in the retroscapular area, where
they were connected with a plastic adapter, in order to
avoid the risk of removal by the animal. In male rats sub-
mitted to discontinuous cystometry, the free end of blad-
der cannula was connected to a swivel at the top of the
Table 1: Effect of intravenous administration of oxybutynin on cystometrographic parameters in anesthetized rats
BVC (ml) TP (mmHg) MP (mmHg) HFO (number) HFO (amplitude)
Controls
Before 0.47 ± 0.04 4.74 ± 0.55 25.0 ± 3.6 4.2 ± 0.2 1.82 ± 0.19
After 0.47 ± 0.04 4.88 ± 0.58 20.9 ± 2.0 4.6 ± 0.2 1.63 ± 0.11
Oxybutynin 0.3 mg/kg
Before 0.44 ± 0.11 3.44 ± 0.84 20.3 ± 2.3 4.6 ± 0.2 1.68 ± 0.27
After 0.27 ± 0.05 2.34 ± 0.51 15.5 ± 1.7 ** 4.2 ± 0.7 1.63 ± 0.24
Data are expressed as mean ± s.e. mean. BVC: bladder volume capacity; TP: threshold pressure; MP: micturition pressure; HFO: high frequency 
oscillations (number and amplitude). * = p < 0.05; ** = p < 0.01 before vs after administration (Student's t test).
Table 2: Effect of intravenous administration of oxybutynin on cystometrographic parameters in conscious obstructed rats
BVC (ml) MV (ml) NVC: frequency (N°/2 min) NVC: amplitude (mmHg)
Controls
Before 1.27 ± 0.16 1.36 ± 0.24 5.3 ± 0.9 5.2 ± 0.9
After 1.14 ± 0.25 1.32 ± 0.30 4.9 ± 0.9 4.9 ± 0.9
Oxybutynin 0.3 mg/kg
Before 1.98 ± 0.12 2.02 ± 0.46 5.9 ± 0.4 11.7 ± 1.8
After 2.58 ± 0.70 2.77 ± 0.50 5.5 ± 0.6 9.7 ± 2.1
Data are expressed as mean ± s.e. mean. BVC: bladder volume capacity; MV: micturition volume; NVC: non-voiding contractions. * = p < 0.05; ** = 
p < 0.01 before vs after administration (Student's t test).BMC Pharmacology 2005, 5:14 http://www.biomedcentral.com/1471-2210/5/14
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cage, thus allowing free movements to animals in a 20 ×
25 cm size cage. A rigid fluid-filled tubing connected to
the swivel provided undistorted transmission of the blad-
der pressure to the transducer, which was placed outside
the cage, at a height corresponding to the position of rat
bladder.
Cystometry procedures
The free tip of the bladder cannula was connected by a T-
shape tube to a pressure transducer and to a peristaltic
pump for a constant rate continuous infusion of saline
solution (at room temperature) into the urinary bladder.
In anesthetized female normal rats, the urodynamic
parameters were recorded continuously using a MacLab/
8SP interface with Chart Software v. 4.1.2. (AD Instru-
ment). In conscious rats, the urodynamic parameters were
obtained from the cystometrogram recorded on a chart
poligraph (Rectigraph SAN-EI 8K).
In anesthetized female rats the following parameters were
evaluated: bladder volume capacity (BVC), defined as the
volume (in ml) of saline infused into the bladder and nec-
essary to induce detrusor contraction followed by micturi-
tion; micturition pressure (MP, in mm Hg) defined as the
maximal intravesical pressure induced by contraction of
the detrusor during micturition; threshold pressure (TP, in
mmHg) i.e. the difference between intraluminar basal
pressure and pressure value recorded just before micturi-
tion; the number (n.HFO) and the amplitude (a.HFO, in
mmHg) of high-frequency oscillations recorded in 1 sec at
the middle of the expulsion time phase.
In conscious female obstructed rats, the number and the
mean amplitude of the spontaneous bladder contractions,
present during bladder filling but without urine emission
and termed "non-voiding contractions" (NVC), were eval-
uated for the 2 min time prior to micturition. In addition,
BVC, MP and micturition volume (MV) were evaluated.
In conscious normal male rats, only BVC and MP values
(defined as above) were obtained from the
cystometrograms.
Cystometric investigation in conscious normal rats
Rats were generally utilized one day after catheter implan-
tation. Some experiments were carried out in rats utilized
5 days after surgery.
On the day of the experiment, conscious rats were placed
in Bollman's cages and the recording of cystometro-
graphic parameters started after a stabilization period of
20 min. Saline infusion into the bladder was generally at
a constant rate of about 0.1 ml/min. Some experiments
were performed decreasing the rate of saline infusion at
0.05 and 0.025 ml/min. Basal BVC and MP values were
evaluated as the mean of two complete and reproducible
cystometrograms during the pretreatment period (basal).
Then the animals were treated intravenously or orally
with the test compound (or vehicle) under continuous
infusion of the bladder with saline, and changes in BVC
and MP were evaluated for 60 or 300 min, respectively.
Discontinuous cystometry was performed for 12 hours (2
hours for basal recording and 10 hours after
administration of drugs), through a discontinuous infu-
sion of warm saline solution into the urinary bladder (1 h
cycle) as reported in Fig. 11.
The effect of the following treatments was evaluated:
- i.v. administration of tolterodine (0.03 – 0.1 and 0.3 mg/
kg) and oxybutynin (0.1 and 0.3 mg/kg) in conscious rats
utilized 1 day after catheter implantation;
Table 3: Summary of results obtained after treatment with tolterodine and/or oxybutynin in the different models/conditions utilized.
Models/conditions Effect on BVC Effect on MP
Conscious rats – 1 day after surgery – i.v. and p.o. administration = ↓↓
Conscious (freely-moving/discontinuos cystometry) rats – 1 day after surgery – p.o. administration = ↓
Conscious (cystometry at different rate of filling) rats – 1 day after surgery – p.o. administration = ↓
Conscious (bladder infused with suramin) rats – 1 day after surgery – p.o. administration = ↓
Conscious (bladder infused with acetic acid) rats – 1 day after surgery – p.o. administration = (↑) ↓↓
Conscious (obstructed) rats – 2 days after surgery – i.v. administration = n.e.
Conscious rats – 5 days after surgery – i.v. and p.o. administration = ↓
Anesthetized rats – at the day of surgery – i.v. administration = ↓
= not significant change; ↓: decrease; ↓↓: dose-dependent decrease; n.e. = not evaluated (since the ligature around the urethra was not removed 
before cystometry, peak micturition pressure was not considered in these experiments); = (↑): some non dose-dependent effect was seen after 
tolterodine but not after oxybutynin.BMC Pharmacology 2005, 5:14 http://www.biomedcentral.com/1471-2210/5/14
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- p.o. administration of tolterodine (1 – 3 and 10 mg/kg)
and oxybutynin (1 and 3 mg/kg) in conscious rats utilized
1 day after catheter implantation;
- p.o. administration of oxybutynin (3 mg/kg) in con-
scious freely-moving rats upon discontinuous cystometry;
- p.o. administration of oxybutynin (1 mg/kg) in con-
scious rats utilized 1 day after catheter implantation and
with saline infusion rate of 0.025 and 0.05 ml/min;
- p.o. administration of oxybutynin (3 mg/kg) in con-
scious rats utilized 1 day after catheter implantation and
with suramine infusion into the bladder at 3 × 10-6 and 1
× 10-5 M concentration.
- i.v. administration of tolterodine (0.1 and 0.3 mg/kg) in
conscious rats utilized 5 days after catheter implantation;
- p.o. administration of oxybutynin (1 mg/kg) in con-
scious rats utilized 5 days after catheter implantation;
Cystometric investigation in anesthetized normal rats
Rats were utilized on the day of catheter implantation.
Saline infusion into the bladder was at a constant rate of
about 0.1 ml/min. After stabilization, basal values of the
considered parameters were evaluated as mean value from
the second and third cystometrogram recorded after i.v.
injection of vehicle. Then, the animals were treated with
the compound tested (or again with vehicle for the con-
trol group) and changes induced by treatment were evalu-
ated by considering the value of the cited parameters as
mean of the second and third cystometrogram after
treatment.
The effect of i.v. administration of oxybutynin 0.3 mg/kg
was evaluated.
Cystometric investigation in rats with bladder infused with 
diluted acetic acid
In conscious rats utilized 1 day after catheter implanta-
tion, saline solution was infused into bladder until
stabilization of cystometrograms was achieved. At this
point, bladder infusion was switched from saline to 0.2%
acetic acid solution. Infusion rate was always 0.1 ml/min.
One hr after, the rats were injected intravenously with the
test compound (or vehicle) and changes in BVC and MP
were evaluated for the following 60 min under continu-
ous infusion of acetic acid. The effect of i.v. administra-
tion of tolterodine (0.03 – 0.1 and 0.3 mg/kg) and
oxybutynin (0.1 and 0.3 mg/kg) was evaluated.
Cystometric investigation in conscious obstructed rats
Rats were utilized two days after catheter implantation.
Saline infusion into the bladder was at a constant rate of
about 0.17 ml/min. From the cystometrograms of the
obstructed rats, the number and the mean amplitude of
the spontaneous bladder contractions, present during
bladder filling without urine emission and termed "non-
voiding contractions" (NVC) were evaluated for the 2 min
time prior to micturition. In addition, BVC and micturi-
tion volume (MV) were evaluated. Values of the parame-
ters reported above were expressed as mean values
obtained from two similar cystometrograms recorded just
before (basal values) and as mean of the second and third
Scheme of discontinous cystometry in conscious rats Figure 11
Scheme of discontinous cystometry in conscious rats. Bidirectional arrows indicate hourly periods of bladder infusion, 
vertical arrow indicates drug administration.
First 2hr 3thh 4thh 5thh 6thh 7thh 8thh 9thh 10thh 11thh 12thh
Cystometry
Basal 1 2 3 4 5 6 7 8 9 10
(hours after drugadmin.)
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cystometrogram after treatment. Since the ligature around
the urethra was not removed before cystometry, peak mic-
turition pressure was not considered in these experiments.
The effect of i.v. administration of oxybutynin 0.3 mg/kg
was evaluated.
Data analysis
Data were always expressed as mean ± S.E. of the mean.
Statistical significance of the change of the different
parameters recorded in anesthetized normal rats and con-
scious obstructed rats (before vs after treatment) was eval-
uated by Student's t test for paired data.
Statistical analysis of data involving time-course of BVC
and MP values was performed by S.A.S./STAT software,
version 6.12. The difference between vehicle and active
treatments effect at different times was evaluated on val-
ues (for each rat the value at considered time minus basal
value) of BVC and MP, using the general linear model pro-
cedure, repeated measures ANOVA, a univariate test of
hypotheses for within subjects effects and ANOVA of con-
trast variables.
BVC and MP values of each rat were also transformed in
AUC data. Statistical significance was evaluated by
ANOVA (and Dunnett's test) or by Student's t test.
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